Blachy J. Dávila Saldaña
A5050982925- Immunodeficiency and Autoimmune Disorders
- Hematopoietic Stem Cell Transplantation
- Immune Cell Function and Interaction
- Cytomegalovirus and herpesvirus research
- Virus-based gene therapy research
- T-cell and B-cell Immunology
- Parvovirus B19 Infection Studies
- Autoimmune and Inflammatory Disorders Research
- CAR-T cell therapy research
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Blood disorders and treatments
- Pneumocystis jirovecii pneumonia detection and treatment
- Cystic Fibrosis Research Advances
- Renal Transplantation Outcomes and Treatments
- Polyomavirus and related diseases
- Acute Lymphoblastic Leukemia research
- Transplantation: Methods and Outcomes
- Respiratory viral infections research
- Pericarditis and Cardiac Tamponade
- Mycobacterium research and diagnosis
- Viral gastroenteritis research and epidemiology
- Complement system in diseases
- Acute Myeloid Leukemia Research
- Acupuncture Treatment Research Studies
- Mesenchymal stem cell research
Children's National
2016-2025
George Washington University
2017-2025
Cincinnati Children's Hospital Medical Center
2015-2025
Center for Cancer and Blood Disorders
2023-2024
National Hospital
2022
Temple University Hospital
2018
Oregon Health & Science University
2013
Centers for Disease Control and Prevention
2011
University of Puerto Rico System
2006
Human recombination-activating gene (RAG) deficiency can manifest with distinct clinical and immunological phenotypes. By applying a multiomics approach to large group of RAG-mutated patients, we aimed at characterizing the immunopathology associated each phenotype. Although defective T B cell development is common all phenotypes, patients hypomorphic RAG variants generate cells signatures immune dysregulation produce autoantibodies broad range self-antigens, including type I interferons....
Abstract Transplant-associated thrombotic microangiopathy (TA-TMA) is a severe complication of hematopoietic stem cell transplantation (HSCT). A single-center prospective screening study has shown that the incidence TA-TMA much higher than prior retrospective studies did not systematically screen. These data have been replicated in multicenter study. Our objective was to determine and risk factors for compare outcomes pediatric HSCT patients with without TA-TMA. Patients were prospectively...
Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening, hyperinflammatory syndrome. Emapalumab, fully human monoclonal antibody that neutralizes the proinflammatory cytokine interferon gamma, approved in United States to treat primary HLH (pHLH) patients with refractory, recurrent, or progressive disease, intolerance conventional treatments. REAL-HLH, retrospective study, conducted across 33 US hospitals, evaluated real-world treatment patterns and outcomes treated ≥1 dose of...
Background Mycobacterium tuberculosis (Mtb) infection may cause overt disease or remain latent. Interferon gamma release assays (IGRAs) detect Mtb infection, both latent and manifesting as disease, by measuring whole-blood interferon (IFN-γ) responses to antigens such early secreted antigenic target-6 (ESAT-6), culture filtrate protein 10 (CFP-10), TB7.7. Due a lack of adequate diagnostic standards for confirming IGRA sensitivity detecting has been estimated using patients with...
Primary Immune Regulatory Disorders (PIRD) are an expanding group of diseases caused by gene defects in several different immune pathways, such as regulatory T cell function. Patients with PIRD develop clinical manifestations associated diminished and exaggerated responses. Management these patients is complicated; oftentimes immunosuppressive therapies insufficient, may require hematopoietic transplant (HCT) for treatment. Analysis HCT data have previously focused on a single defect. This...
Abstract Viral infections remain a major risk in immunocompromised pediatric patients, and virus-specific T cell (VST) therapy has been successful for treatment of refractory viral prior studies. We performed phase II multicenter study (NCT03475212) the patients with inborn errors immunity and/or post allogeneic hematopoietic stem transplant using partially-HLA matched VSTs targeting cytomegalovirus, Epstein-Barr virus, or adenovirus. Primary endpoints were feasibility, safety, clinical...
Allogeneic bone marrow transplantation (BMT) is curative therapy for the treatment of patients with severe aplastic anemia (SAA). However, several conditioning regimens can be used BMT. We evaluated transplant BMT in SAA after HLA-matched sibling and unrelated donor For recipients (n = 955), fludarabine (Flu)/cyclophosphamide (Cy)/antithymocyte globulin (ATG) or Cy/ATG led to best survival. The 5-year probabilities survival Flu/Cy/ATG, Cy/ATG, Cy ± Flu, busulfan/Cy were 91%, 80%, 84%,...
Germline mutations in SAMD9 and SAMD9L genes cause MIRAGE (myelodysplasia, infection, restriction of growth, adrenal hypoplasia, genital phenotypes, enteropathy) (OMIM: *610456) ataxia-pancytopenia *611170) syndromes, respectively, are associated with chromosome 7 deletions, myelodysplastic syndrome (MDS), bone marrow failure. In this retrospective series, we report outcomes allogeneic hematopoietic cell transplantation (HCT) patients hematologic disorders SAMD9/SAMD9L mutations. Twelve...
Summary Viral infections are a serious cause of morbidity and mortality following haematopoietic stem cell transplantation (HSCT). Adoptive cellular therapy with virus‐specific T cells (VSTs) has been successful in preventing or treating targeted viruses prior studies, but the composition ex vivo expanded VST critical populations that mediate antiviral activity not well defined. We utilized deep sequencing T‐cell receptor beta chain (TCRB) order to classify track 12 patients who received...